BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

i3 (Basking Ridge, New Jersey) Launches Clinical Informatics Solutions Group


4/20/2009 2:27:00 PM

BASKING RIDGE, NJ, April 20, 2009—A new retrospective study of 232 clinical trial investigators shows that i3’s ratings enhance the ability to predict success in patient enrollment and retention. The i3 system uses de-identified insurance claims to calculate the percentage of each investigator’s patients who qualify for a trial. Success is predicted when an investigator has a high percentage of patients who match the trial’s criteria. The study was conducted by the new Clinical Informatics team housed within i3 Pharma Informatics.

Clinical Informatics Solutions uses one of the nation's largest private databases of insurance claims to create solutions to improve the speed and likelihood of success of trials. This study leveraged its feasibility analysis service which, combined with related capabilities, is used to rank all physicians who might be investigators, rank geographies for patient availability, and determine trial feasibility based on national patient counts. The site selection capability pinpoints both the investigators with the most patients, as well as those geographies with the highest concentrations of appropriate patients for more successful trials.

The study showed the top 30 percent of investigators—physicians who are high enrollers—recruit 70 percent of the trial’s total patients.

“Our capabilities find the high enrollers, increasing the trial’s speed,” said Bill Gwinn, vice president of Clinical Informatics. “Industry data show that 70 percent of American trials run late. Our feasibility analysis service helps identify unrealistic protocol criteria and helps our sponsors plan more sites when patient counts are low.”

Gwinn joins i3 as an expert in quantitative analysis for selecting the best clinical trial sites and finding new patients. His past experience includes positions at Inclinix and The Medstat Group at Thomson Reuters.

About i3

i3, a global Ingenix company, provides integrated scientific strategies and solutions throughout the pharmaceutical product lifecycle. It is composed of i3 Research, a therapeutically specialized contract research organization; i3 Drug Safety, engaged in pharmacovigilance and epidemiology; i3 Pharma Informatics, a data, science and technology provider of market analytics; i3 Statprobe, a leader in comprehensive data services; i3 Pharma Resourcing, a world-class staffing partner; and i3 Innovus, delivering the science and solutions to achieve marketplace success. i3 helps companies gain sharper insights that lead to better patient care. For more information, visit www.i3global.com.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES